Ibrutinib for Schnitzler syndrome with concurrent hematologic malignancy

Jani P, et al.

J Oncol Pract 14(6):387-388 · 2018

Grade Ccase reportn=1engOpen AccessVerified
DOI ↗PubMed ↗Full Text (PMC) ↗

Abstract

[Abstract not available]

Key Findings

  • ●First report of ibrutinib for Schnitzler syndrome
  • ●Concurrent hematologic malignancy

Subject Classification

AdenineAged, 80 and overExanthemaHistocytochemistryHumansMalePiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesSchnitzler SyndromeSkinTreatment Outcome

Referenced in (1 disease)

Schnitzler Syndrome

Validation history

Full log →
  1. passsource metadataJun 1, 2026, 02:25 PMby pubmed-api

    DOI corrected to the PubMed/Crossref-registered value; the prior stored DOI was fabricated (resolved to an unrelated or non-existent article). A duplicate entry carrying a malformed PMID was removed from the manifest.

    tools: pubmed.esummary, crossref.works

ID: pmid-29558252DOI: 10.1200/JOP.18.00050PMID: 29558252PMCID: PMC7846060